Development of the General Scale Observance for Chronic Diseases

Development of the General Scale Observance for Chronic Diseases (EGOMAC)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02885129

Acronym

EGOMAC

Enrollment

397

Registered

2016-08-31

Start date

2014-06-30

Completion date

2017-04-30

Last updated

2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Diseases

Brief summary

The main objective is to assess the measurement characteristics (validity, reproducibility) and the invariance of EGOMAC scale in a population of consultants in diabetology, cardiology and rheumatology hospital and liberal and hospital oncology and Infectious disease, by following the evolution of patient compliance at D0 and D15. The second objective is to assess the sensitivity to change of scale EGOMAC following developments compliance 3 months.

Detailed description

During a routine appointment (D0), the patient filled a newsletter and a questionnaire to complete. The doctor collects medical informations for the case report form. At the end of the first consultation (D0), an additional EGOMAC scale and a stamped envelope is delivered to the patient by asking him to fill that scale to 15 days and return it by Post Office (reproducibility study). Finally, a new scale will be addressed to the patient at the end of 3 months, which will return by Post Office too (stability study).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient age of 18 years * from routine patient counseling * with at least one of these diseases : heart failure, hypertension, coronary disease, type 2 diabetes, osteoarthritis of the knee or hip, osteoporosis, inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy), cancer ( with only non-hormonal oral anti cancer treatments) and HIV. * patient can read the French language in order to complete the self -administered questionnaire * patient agreeing to participate in the study

Exclusion criteria

* patient treated for more than 3 conditions mentioned in the inclusion criteria ( * patient receiving no drug prescription or recommendation of lifestyle or diet (for example consultationpurely diagnostic ).

Design outcomes

Primary

Measure	Time frame
EGOMAC questionnaire	baseline
Change in EGOMAC questionnaire	15 days

Countries

France

Outcome results